DRG Epidemiology’s coverage of neuropathic back pain (NBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of NBP for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered.
DRG Epidemiology’s NBP forecast will answer the following questions:
- Of all people with NBP, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with NBP, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NBP over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
- Neuropathic Back Pain - Epidemiology - Emerging Markets
- Key Findings
- Total Prevalence of Neuropathic Back Pain per 100 People Aged 20+ in 2018
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Neuropathic Back Pain over the Next Ten Years
- Epidemiology Data
- Total Prevalent Cases
- Diagnosed Prevalent Cases
- Drug-Treated Cases
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Neuropathic Back Pain
- Studies Excluded from the Analysis of Neuropathic Back Pain
- Risk/Protective Factors
- Risk/Protective Factors for Neuropathic Back Pain
- Literature Review
Author(s): Mudasir Khan, M.P.H.; Abey John, MPH
Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.
Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.
Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.
Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.